Winteam Pharmaceutical Group Limited provided earnings guidance for the six months ended June 30, 2012. For the period, the Group is expected to record a significant increase in net profit as compared to that of the six months ended June 30, 2011. The profit increase is expected to be mainly attributable to the steady growth in sales of the Group; effective cost control over sales and marketing expenses; and the decrease in cost of raw materials, as the result of the decline in price of Chinese herbal medicines commonly used by the Group.